# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001571049-17-003521
Filing Date
2017-04-12
Accepted
2017-04-12 16:35:57
Documents
6
Effectiveness Date
2017-04-12

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | t1700099x2_def14a.htm | DEFA14A | 24783
2 | GRAPHIC | t1700099_pg1def14a.jpg | GRAPHIC | 183113
3 | GRAPHIC | t1700099_pg2def14a.jpg | GRAPHIC | 313411
4 | GRAPHIC | t1700099_pg3def14a.jpg | GRAPHIC | 204864
5 | GRAPHIC | t1700099_pg4def14a.jpg | GRAPHIC | 133272
6 | GRAPHIC | t1700099_pg5def14a.jpg | GRAPHIC | 9945
| Complete submission text file | 0001571049-17-003521.txt |  | 1173210

Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-50626 | Film No.: 17758331
SIC: 2834 Pharmaceutical Preparations